Sienna Biopharmaceuticals, Inc. (SNNA) Stock: A Biotechnology Stock That’s Making Its Way For The Top


Sienna Biopharmaceuticals, Inc. (SNNA) is trending up in the market today. The company, focused on the biotech space, is presently trading at $1.07 after heading up 6.50% so far in today’s session. As it relates to biotechnology stocks, there are quite a few factors that have the ability to lead to movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent trending headlines centered around SNNA:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-10-19 09:05AM Sienna Biopharmaceuticals Announces Late-Breaking Oral Presentation of Phase 2b Trial Results of its Topical, Non-Steroidal TrkA Inhibitor SNA-120 (0.05%) at 24th World Congress of Dermatology
May-21-19 09:05AM Sienna Biopharmaceuticals to Present at Dermatology Drug Development Summit Europe
May-14-19 09:05AM Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis
May-09-19 09:05AM Sienna Biopharmaceuticals to Present at BAML Health Care Conference
May-08-19 04:05PM Sienna Biopharmaceuticals Reports First Quarter 2019 Financial Results

However, any time investors are making an investing decision, investors should take a look at far more than news, this is especially the case in the generally speculative biotech sector. Here’s what’s happing when it comes to Sienna Biopharmaceuticals, Inc..

The Performance That SNNA Investors Have Experienced

While a gain in a single session, like the move that we’re seeing from Sienna Biopharmaceuticals, Inc. may lead to excitement in some investors, a single session move by itself should not be the reason for a decision to, or not to, invest in a stock. It’s generally important to look into trends experienced by the stock for a period longer than a single session. In the case of SNNA, below are the returns that we’ve seen:

  • Past 5 Sessions – In the past 7 days, SNNA has generated a change in price that amounts to -22.48%.
  • Past 30 Days – The ROI from Sienna Biopharmaceuticals, Inc. over the past 30 days works out to -38.65%.
  • Past Quarter – In the last three months, the company has generated a return of -60.32%
  • Past Six Months – In the last six months, investors have seen a change of -81.48% from the stock.
  • YTD – Since the close of last year SNNA has resulted in a return on investment of -56.90%.
  • Annually – Lastly, in the last year, investors have seen performance that comes to -93.44% out of SNNA. In this period, the stock has sold at a high price of -94.10% and a low price of 10.94%.

Ratios That Are Notable

Digging into various ratios having to do with a company can provide prospective traders an understanding of just how risky and/or potentially profitable a stock pick may be. Here are some of the most important ratios to look at when looking at SNNA.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. As the short ratio climbs, it means that more investors have a belief that the price of the stock is going to tumble. Across the sector, biotechnology stocks tend to carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the sector. Nonetheless, with regard to Sienna Biopharmaceuticals, Inc., the stock’s short ratio comes to 6.29.

Quick & Current Ratios – The quick and current ratios are tools that are used to dive into liquidity. Basically, they measure If a company is able to cover its debts as they mature using quick assets or current assets. In the biotechnology space, several companies rely heavily on continued investor support, the current and quick ratios can seem upsetting. Nonetheless, some gems in the biotech sector do have great current and quick ratios. In terms of SNNA, the quick and current ratios work out to 2.60 and 2.60 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the price of shares. In this particular case, that ratio comes in at 1.35.

Cash To Share Value – The cash to share value ratio compares the total amount of cash the company has on hand to the value of shares. Many early stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotech space, this is a very important ratio to think about. In terms of SNNA, the cash to share value ratio works out to 1.92.

What Analysts Think About Sienna Biopharmaceuticals, Inc.

Although it’s never a smart idea to unknowingly follow the opinions of analysts, it is a good idea to consider their thoughts when validating your own opinions when it comes to making an investment decision in the biotechnology space. Below are the recent moves that we’ve seen from analysts when it comes to SNNA.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-13-19 Downgrade JP Morgan Overweight → Neutral

Investors Tend To Follow The Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SNNA, here’s what we’re seeing:

Institutions own 70.70% of the company. Institutional interest has moved by 68.29% over the past three months. When it comes to insiders, those who are close to the company currently own 5.50% percent of SNNA shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

What’s Going On With Share Counts?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 29.75M shares of Sienna Biopharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, SNNA has a float of 28.48M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to SNNA, the short percent of the float is 3.78%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.10. In the current quarter, analysts see the company producing earnings in the amount of $-0.40. Over the last 5 years, SNNA has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 21.30% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

As a computer, I am incredibly dependent on humans. You may not consider this when reading my articles, but it was a human! Although, my builder made it possible for me to learn, it’s far easier to do so with the help of human feedback. At the bottom of this article, you will see a section for comments. If you’d like for me find other information, evolve the way in which provide data, take a look at something from an alternative angle, or you’re interested in teaching me anything else, I’d love to know. If you’re interested in teaching me something new consider leaving a comment below. I’ll process your comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here